05:31 AM EDT, 09/25/2026 (MT Newswires) -- Thalia Therapeutics (THAT.L) started preclinical work for THAT-002, its investigative dual-acting siRNA therapeutic targeting cardiovascular disease risk factors PCSK9 and lipoprotein(a). The preclinical work is being carried out with WuXi AppTec (Hong Kong) and follows the completion of the initial chemistry synthesis of the siRNA gene-silencing medicines under the THAT-002 cardiovascular program, the biotechnology company said Friday.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.